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In situ gels are systems which are applied as solutions or suspensions and are capable of undergoing
rapid sol-to-gel transformation triggered by external stimulus such as temperature, pH etc. on instilla-
tion. The aim of the present study was to formulate and evaluate pH responsive in-situ gel for ophthalmic
delivery. Ciproﬂoxacin hydrochloride is popularly used as a broad spectrum antibiotic in the treatment of
corneal ulcers of ocular infections. However, rapid dilution on instillation, wash out, poor retention of
drug concentration delimit the therapeutic beneﬁts of the drug when used in form of conventional eye
drops. Sodium alginate, an ophthalmic gel forming mucoadhesive polymer was chosen as polymer which
undergoes instantaneous gel formation due to formation of calcium alginate by virtue of its interaction
with divalent cation (Caþ2) present in lachrymal ﬂuid. Hydroxy Propyl Methyl Cellulose (HPMC K4M and
E5 0LV) was further incorporated as a viscosity enhancer in order to achieve the desired consistency so as
to facilitate sustained drug release. The developed formulations were evaluated for clarity, pH mea-
surement, gelling capacity, drug content, rheological study, and in vitro drug release. Thus, in situ gel
based systems containing gums can be a valuable approach for ophthalmic drug delivery when compared
to conventional systems.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the major limitations faced in ophthalmic delivery is the
attainment and retention of optimum drug concentration at the site
of action within the eye. Various ophthalmic dosage forms, like so-
lutions, ointments, gels and polymeric inserts have been investigated
in an attempt to extend the ocular residence time of medications for
topical application to the eye [1]. The corneal contact time has been
increased to varying degrees by these dosage forms. But, they have
not been unanimously accepted, because of blurred vision (e.g.
ointments) or lack of patient compliance (e.g. inserts).
The eye drops have very poor bioavailability due to their rapid
washout during lachrymation in eyes. Most of the systems are
applied as solutions or suspensions. The rapid pre-corneal elim-
ination observed with conventional ocular formulations ends in
poor drug bio-availability. Ease of administration in case of highly
viscous solution and gel forms retard its use and patient com-
pliance. The blurred vision and the lachrymation are associated
with the dosage form involving hydrogel.
So, these may be overcome by fabricating the drug as an open access article under the CC
anesh Circle, Anand 388001,
akwana).formulation that undergoes instantaneous in situ gel formation
upon ophthalmic administration. They undergo gelation after in-
stillation due to physico-chemical changes occurring in the eye. It
increases the pre-corneal residence time and better bioavailability
of drug can be achieved by formulating in situ gel. The present
work describes the “formulation and evaluation of in situ gel
forming ophthalmic formulation containing ciproﬂoxacin hydro-
chloride”. In which in situ phase transition occurs on the surface of
the cornea. At time of instillation dosage form is in solution phase
and soon later upon coming in contact with calcium ion with
surrounding pH of 7.4 it turns into transparent gel depo. Thus, this
type of formulation has beneﬁt of both solutions as well gels they
may improve the retention time of the formulation as well the
drug, accuracy and ease of administration [1–4].
Ciproﬂoxacin hydrochloride is a pale yellow, crystalline powder
which contains Fluoroquinolone group. Ciproﬂoxacin hydro-
chloride is used as an antibacterial agent in the treatment of cor-
neal ulcers caused by susceptible strains of bacteria, including
Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aur-
eus, Staphylococcus epidermidis, Streptococcus pneumonia, Strepto-
coccus and conjunctivitis, bacterial (treatment) of conjunctivitis
caused by Haemophilus inﬂuenzae, S. aureus, S. epidermidis, S.
pneumoniae, and Streptococcus [5,6] (Fig. 1).
Ciproﬂoxacin's bactericidal action is due to interference with
the enzyme DNA gyrase, which is needed for the synthesis ofBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Structure of ciproﬂoxacin hydrochloride.
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tiplication of bacterial cell.
In situ gelling systems consist of polymer that exhibit sol-to-gel
phase transitions in the cul-de-sac which improves patient com-
pliance due to change in speciﬁc physico-chemical parameters like
pH, temperature and ionic strength in the environment [8]. The
sol-to-gel phase transition on the eye surface depending on the
different methods employed which consist of thermo-sensitive,
ion-activated and electric-sensitive, magnetic ﬁeld-sensitive, ul-
trasonic-sensitive and chemical material-sensitive varieties. But
above them the most commonly methods are as follows:1. pH-triggered system (e.g. cellulose acetate hydrogen phthalate
latex),2. temperature dependent system (eg. pluronics and tetronics),
and3. ion activated system (eg. gelrite) [9,10].
The present work is based on the1. pH triggered system and
2. ion activated system.In situ gel based drug delivery systems consist of active phar-
maceutical ingredients, polymer, co-polymer and excipients. So-
dium alginate, an ophthalmic gel forming mucoadhesive polymer
was chosen, as the polymer and Hydroxy Propyl Methyl Cellulose
(HPMC) as copolymer.
Sodium alginate, family of linear un-branched polysaccharides,
the sodium salt of alginic acid, is a natural hydrophilic poly-
saccharide containing two types of monomers, β-D-mannuronic
acid (M units) and α-L glucuronic acid (G units) residues.
The polymer, Sodium alginate, which undergoes instantaneousFig. 2. UV visible spectra of ciproﬂogel formation due to formation of calcium alginate by virtue of its
interaction with divalent cation (Caþ2) present in lachrymal ﬂuid
(pH 7.4). Alginate can be ionically crosslinked in the presence of
divalent cations.
Hydroxy Propyl Methyl Cellulose (HPMC) is incorporated as a
viscosity enhancer to further aid in accomplishment of sustained
drug delivery. HPMC is semisynthetic, inert, viscoelastic polymer
which is non-ionic nontoxic, a good carrier for pharmaceutical
application which exhibits high swelling capacity [11–14].2. Materials and method
Ciproﬂoxacin hydrochloride was obtained from chitin chem
(Vadodara), Sodium alginate and Hydroxy propyl methyl cellulose
(HPMC E5 0LV and K4M) were obtained from Dutt enterprise,
Renchem Company. All other chemicals and reagents were of
analytical grade procured from CDH chemicals.
2.1. Analytical method development
2.1.1. Determination of λmax of ciproﬂoxacin hydrochloride
For the determination of absorption maxima, stock solution
(1000 mg/ml) was prepared by weighing 100 mg (0.1 g) drug and
dissolving it in 100 ml volumetric ﬂask and making the volume to
the mark with Methanol. 10 ml of standard stock solution was
taken in 100 ml volumetric ﬂask and making the volume to the
mark with methanol to make 100 mg/ml of ciproﬂoxacin. Serial
dilutions with concentrations 2, 4, 6, 8 and 10 mg/ml were pre-
pared by transferring 0.2, 0.4, 0.6, 0.8 and 1.0 ml of the stock so-
lution in 10 ml volumetric ﬂask and makeup the volume with
phosphate buffer 7.4 up to the mark. The resulting solution was
scanned between 200 and 400 nm using UV–visible spectro-
photometer UV 1400, Shimadzu [15] (Figs. 2 and 3).
2.2. Formulation development and evaluation
2.2.1. Formulation of ciproﬂoxacin hydrochloride in situ gel
Table 1 and Figs 4 and 5.
2.3. Characterization of formulation
2.3.1. FT-IR studies
The IR spectra were recorded on Thermo Nicolet, Avatar 370.
FTIR spectra of sodium alginate, HPMC and the drug (Ciproﬂoxacinxacin hydrochloride at 272 nm.
Fig. 3. calibration curve of Ciproﬂoxacin Hydrochloride.
Table 1
Formulation of in situ gel.
Ingredients IG-1 IG-2 IG-3 IG-4
Ciproﬂoxacin HCl (g) 0.3 0.3 0.3 0.3
Sodium alginate (g) 0.5 1.0 1.5 0.5
HPMC (g) 0.5 0.5 0.5 –
Distilled water (ml) 100 100 100 100
Fig. 5. Formulations and physiological condition of in situ gel [16].
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tween 4000 and 500 cm1 [6,17]. FT-IR study of drug and polymer
mixture along with water (in situ mixture) is shown in Fig. 6.
2.3.2. Clarity
Clarity test was observed by visual inspection under a good
light, viewed against a black and white background, with the
contents set in motion with a swirling action. Also it was observed
for formation of turbidity or any unwanted particles dispersed in
the solution [3,18,19].
2.3.3. Gelling capacity
The gelling capacity of the prepared formulation was de-
termined by placing a drop of the formulation in a beaker con-
taining 50 ml of freshly prepared concentrated calcium chloride
solution and was visually observed for gelling time. Coding for the
gelling capacity described in Table 2 [2,3].
2.3.4. Rheological studies
The primitive ophthalmic solution, suspension, and ointment
dosage forms are clearly no longer sufﬁcient to combat these
diseases, and current research and development efforts to design
better therapeutic systems are the primary focus of this research
work. The aim of the present investigation is to formulate an
in situ gel and from our prior knowledge we know that gels showFig. 4. Formulation othixotropic behaviour, so rheological studies are to be performed.
The viscosity measurements were carried out using Brookﬁeld
viscometer model DVII. The developed formulations were placed
in the sampler tube using spindle no. 4. Viscosity of the prepared
formulations was measured by using Research Rotator and Oscil-
latory Rheometer. The gel under study was placed in the small
sample holder and the spindle was lowered perpendicularly into
it. The spindle was rotated at varying speeds and the suitable
speed was selected [20]. Rheological studies of formulation are
shown in Table 4.2.3.5. Measurement of pH
Each formulated batch, pH was measured using pH metre
which was previously calibrated using standard buffers of pH
4 and pH 7 as per the established procedure [17,21].2.3.6. Drug content
1 ml of the developed formulation was dissolved in 100 ml
phosphate buffer (pH¼7.4) followed by spectrophotometrically
estimation of the aliquot to determine drug concentration [2].
Appearance, pH, gelling capacity and drug content (results of
in situ gel) is shown in Table 3.2.3.7. In vitro dissolution studies
Dissolution studies of samples were performed using Franz
diffusion apparatus and phosphate buffer (pH¼7.4) as a dissolu-
tion medium. Phosphate buffer with pH 7.4 will simulate the la-
chrymal ﬂuid [23]. The temperature was maintained at 3770.5 °C
with the speed of rotation maintained at 100 rpm. The samples
were withdrawn at various time intervals and analysed spectro-
photometrically for the drug content [5].f in situ gel [2].
Fig. 6. FT-IR study of drug and polymer mixture along with water (in situ mixture).
Table 2
Coding for the gelling capacity.
Observation Coding
No gelation –
Gelation occurred in few minutes and remained for few hour þ
Gelation immediate, remained for few hour þþ
Gelation immediate, and for extended period þþþ
Very stiff gel þþþþ
Table 3
Results of in situ gel.
Formulation code Appearance pH Gelling capacity % Drug
content
IG-1 Transparent solution 6.55 þþ 84.07
IG-2 Transparent solution 6.58 þþ 87.00
IG-3 Transparent solution 6.53 þþþ 92.43
IG-4 Transparent solution 6.49  82.13
Table 4
Rheological studies of formulation.
Formulation code Viscosity of solution (Pa s) Viscosity of in situ gel (Pa s)
IG-1 0.0163 89.5
IG-2 0.0447 266
IG-3 0.189 856
IG-4 0.00466 0.147
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The two main prerequisites of an in situ gelling system are
viscosity and gelling capacity. Aqueous solutions of varying con-
centrations of HPLC and alginate were prepared and evaluated for
viscosity and gelling capacity. Different concentrations of HPMC
and sodium alginate were tailored and their effects were observed.
Of them the one with suitable consistency required for in situ
gelling was considered for further study.
Alginate forms stable hydrogel in the presence of certain di-
valent cations (e.g. Ca2þ and Sr2þ) through the ionic interaction
between the cation and the carboxyl functional group of G moi-
eties located on the polymer chain [16,20].3.1. FT-IR studies
Drug-excipients compatibility study was performed by FTIR
technique. The IR spectra of the solution were taken, which in-
dicate no interaction between ciproﬂoxacin HCl and polymers
[6,17].
FT-IR spectrum of drug and polymer mixture shows char-
acteristic peaks at 3364 cm1 indicates the presence of carboxylic
group ,1643 cm1 exhibits alkenes, 1420 cm1 indicates the pre-
sence of aromatic ring, 1396 cm1 exhibits carboxylic acids,
1342 cm1 indicates alkyl halides, 1311 cm1 indicates ester,
1273 cm1 indicates alkyl halide, and 1227 cm1 indicates amine
oxide.
From the spectral study it was observed that there was no
signiﬁcant change in the peaks of drug polymer mixture. Hence,
no speciﬁc interaction was observed between the drug and the
polymers used in the formulations (Fig. 7).
3.2. Clarity and pH
The formulations (IG1–IG4) were prepared by using various
concentrations of sodium alginate along with HPMC in different
ratios. All the formulations prepared were clear without any tur-
bidity and suspended particles or impurities.
The pH of in situ gel solution was found to be around 6.49–6.58
(Table 3) for all the formulations. The formulation IG 3 has 6.53 pH
which is an acceptable range for ophthalmic preparations.
3.3. Gelling capacity
Gelling capacity is coded as describe in Table 2. According that
IG 3 shows immediate gelation and for extended period (Fig. 8).
3.4. Rheological studies
The viscosity was directly dependent on the polymeric content
of the formulations. Addition of HPMC led to increase in the
viscosity of formulations and exhibited more pseudo-plasticity
(IG1–IG3) as compared to IG 4 batch prepared without HPMC. The
higher concentration of sodium alginate and HPMC among the
developed formulations IG 3 gives good results which are selected
as optimized batch.
The formulation which is in the solution form should have an
optimum viscosity that will allow for easy instillation into the eye,
which would undergo a rapid sol to gel transition.
Fig. 7. FT-IR spectra of drug and optimized formulation.
Fig. 8. Dissolution study of in situ gel.
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3.5.1. For in situ gel: 3 mg
Percentage drug release in case of in situ gel of Ciproﬂoxacin
hydrochloride was found to be 67.02% release in 7 h. Thus the in
vitro dissolution test indicated the sustained release nature of
in situ gel of Ciproﬂoxacin hydrochloride.4. Conclusion
Ciproﬂoxacin hydrochloride was successfully formulated as
in situ gel-forming eye drops using sodium alginate and HPMC.
Thus the above results demonstrate that the alginate and HPMC
mixture can be used as an in situ gelling vehicle to enhance ocular
bioavailability and patient compliance [22].
Physicochemical characterization and in vitro drug release
studies indicated that the developed formulation (IG 3) may prove
to be a viable alternative to conventional eye drops and ointment
in terms of ease of administration with added beneﬁts of sustained
drug release which may ultimately result into improved patient
compliance.Conﬂicts of interest
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